Disrupting stress management in cancer cells
The laundry is still undone, the bicycle needs fixing, and the bills haven’t been paid…
Author ONA Editor
ONA Editor
The ONA Editor curates oncology news, views and reviews from Australia and around the world for our readers. In aggregated content, original sources will be acknowledged in the article footer.
Myeloid immune cells may offer a new target for immunotherapy in liver cancer
The most common type of liver cancer in children, hepatoblastoma, surprisingly appears to contain many…
New insight into the response mechanism of arsenic in treating acute promyelocytic leukaemia
In this study, researchers conducted a comprehensive characterisation of the tumour microenvironment in APL patients…
Kidney cancer cases are projected to double by 2050
Modifiable risk factors such as obesity, smoking, lack of exercise, diabetes, and hypertension are projected…
NCCN Guidelines Navigator for breast cancer genetic testing and treatment
The National Comprehensive Cancer Network® (NCCN®)—a nonprofit responsible for globally utilised guidelines for cancer care—is sharing…
Could reducing inflammation help combat fatigue in people with early-stage breast cancer?
New research reveals that inflammatory responses may play a role in different types of fatigue…
ASTRO 2025: Pulsed low dose rate chemoradiation therapy can significantly reduce side effects while maintaining treatment effectiveness for patients with oesophageal cancer and non-small cell lung cancer
Researchers have demonstrated that pulsed low dose rate (PLDR) chemoradiation therapy can significantly reduce side effects while…
ASTRO 2025: Patient-reported outcome analysis of NRG Oncology trial in limited-stage small cell lung cancer suggests quality of life benefit with twice – (vs once -) daily radiation
Previously, the primary endpoint results of the NRG-LU005 study assessing the addition of the immunotherapy…
FDA approves imlunestrant for ER-positive, HER2-negative, ESR1-mutated advanced or metastatic breast cancer
On September 25, 2025, the Food and Drug Administration approved imlunestrant, an oestrogen receptor antagonist,…
ASTRO 2025: Health-related quality of life analysis shows benefit in both proton and photon radiation options in breast cancer patients
Results from the health-related quality of life (HRQOL) analysis of the University of Pennsylvania and…